406 results on '"Dangond, Fernando"'
Search Results
102. Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension (P5.379)
103. Cladribine comprimés dans le traitement de patients atteints de sclérose en plaques (SEP) : une analyse intégrée de la tolérance issue du programme de développement clinique pour le traitement de la SEP
104. Éfficacité durable de Cladribine comprimés chez les patients atteints de (SEP) : analyse des taux de poussées et des patients sans poussées dans les études CLARITY et CLARITY Extension
105. Efficacité clinique de Cladribine comprimés (CC) chez les patients atteints de récurrente-rémittente (SEP-RR) : résultats finaux de l’étude d’extension de Phase IIIb à 120 semaines de l’étude CLARITY
106. Analyse rétrospective d’efficacité chez les patients atteints de (SEP) répondant aux critères de McDonald 2010 dans l’étude ORACLE-MS
107. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
108. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
109. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
110. Slowing of Disability Progression Based on 6-Month Confirmed EDSS in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets in the CLARITY Study: A Post-Hoc Subgroup Analysis (P3.058)
111. Predictive Value of Early MRI Measures for Long-Term Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis Receiving IFN β-1a SC tiw or IFN β-1a IM qw: Post Hoc Analyses of the EVIDENCE Study (P6.189)
112. Magnetic Resonance Imaging (MRI) Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets: Results from the 120-Week Phase IIIb Extension of the CLARITY Study (P2.114)
113. Interferon β-1a SC tiw Reduces Mild to Moderate and Moderate to Severe Relapses and Disease Activity over 1 Year in Patients with Relapsing MS: Post Hoc Analyses of PRISMS Data (P3.036)
114. Efficacy of Cladribine Tablets in ORACLE Study Patients Who Retrospectively Met 2010 McDonald Multiple Sclerosis (MS) Criteria at Baseline (P3.035)
115. Predictive Value of 6-Month T2 and Enhancing Lesions Among Patients with RRMS Receiving Interferon β-1a Subcutaneously Thrice Weekly or Placebo: Post Hoc Analyses of PRISMS Data (P1.401)
116. Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.095)
117. Efficacy of Cladribine Tablets as Add-On to IFN-beta Therapy in Patients with Active Relapsing MS: Final Results from the Phase II ONWARD Study (P3.029)
118. Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.028)
119. MRI Frequency and No Evidence of Disease Activity Status Among Patients with RRMS Receiving IFN β-1a SC tiw or IFN β-1a IM qw: Post Hoc Analyses of EVIDENCE (P6.190)
120. Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS
121. Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial
122. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
123. Early Onset and Predictive Value of MRI Measures among Patients Receiving Interferon Beta-1a SC tiw for RRMS: Post Hoc Analyses of PRISMS-2 Data (P7.254)
124. No Evidence of Disease Activity in Patients with Relapsing MS Treated with Interferon Beta-1a SC tiw versus Interferon Beta-1a IM qw: Subgroup Analyses of the EVIDENCE Study (P7.271)
125. Early Effects of Interferon Beta-1a SC tiw Versus Interferon Beta-1a IM qw on MRI Outcomes in Patients with Relapsing MS in the EVIDENCE Study (P7.257)
126. No Evidence of Disease Activity in Patients with Relapsing MS Treated with Interferon Beta-1a SC tiw Versus Interferon Beta-1a IM qw in the EVIDENCE Study (P7.220)
127. 1-Year Efficacy and Tolerability Results for IFN Beta-1a SC tiw Treatment and Predictive Value of 6-Month MRI: Exploratory Analysis of PRISMS Data in Patients with RRMS (P7.242)
128. Relationship between Cognitive Status and Perception of Ease of Use of an Electronic Autoinjector for Subcutaneous Interferon Beta-1a (P3.225)
129. Development of Chronic Black Holes (CBH) Predicts Long Term Disability: Post-hoc Analysis of Magnetic Resonance Imaging (MRI) Data in the PRISMS Study (P7.251)
130. Quality of life perceptions correlate with longitudinal clinical relapse reduction metrics in patients treated with subcutaneous interferon beta-1a given three times a week. (P1.113)
131. A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing–remitting multiple sclerosis
132. Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein
133. Relationship between Immunological Markers and Short-Term Brain Volume Changes in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Interferon Beta-1a (P3.146)
134. Associations Between Changes in Ferritin Levels and Susceptibility-Weighted Imaging Filtered Phase in Patients with Relapsing-Remitting Multiple Sclerosis over Six Months Therapy with Interferon Beta-1a (P6.115)
135. Correlations between Immunological Biomarkers and Conventional and Advanced MRI Measures Following Interferon Beta-1a Treatment for Relapsing-Remitting Multiple Sclerosis (P3.147)
136. Changes in Immunological Biomarkers in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Interferon Beta-1a (P4.132)
137. Subcutaneous Interferon Beta-1a Decreases the Evolution of Gadolinium-Enhancing Lesions Into Chronic Black Holes in Relapsing Multiple Sclerosis (P7.240)
138. Early and Consistent Reduction in Relapses among Patients with Relapsing-Remitting Multiple Sclerosis Receiving Subcutaneous Interferon Beta-1a: A Post-Hoc Analysis of PRISMS Data (P3.182)
139. In VitroAssessment of the Biologic Activity of Interferon Beta Formulations used for the Treatment of Relapsing Multiple Sclerosis
140. Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsing–Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study
141. Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study
142. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study
143. Prognostic immunological markers in patients with relapsing-remitting multiple sclerosis: a prospective magnetization transfer brain imaging study (P3117)
144. Interferon beta-1a Treatment Inhibits Th1- and Th17-Cell Responses in Patients with Relapsing–Remitting Multiple Sclerosis (P05.144)
145. Interferon beta-1a modulation of B cells (161.12)
146. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study
147. Histone deacetylase 3 represses HTLV-1 tax transcription
148. Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis
149. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice
150. Functional Characterization of JMJD2A, a Histone Deacetylase- and Retinoblastoma-binding Protein
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.